Skip to main content
OpenTrials
Completed

NCT Number: NCT02146391

Study to Evaluate the Effect of Food Upon the Pharmacokinetics of Androxal

This study is an open-label, randomized, single-center, single-dose, two-way crossover study of the PK properties of Androxal in healthy male subjects. Twelve male subjects will each receive a single dose of Androxal 25 mg in both the fed and fasting state.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–60 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Speak, read, and understand English or Spanish and is willing and able to provide written informed consent on an IRB-approved form prior to the initiation of any study procedures;
  • Male; age 18-60 with a BMI of 25-42 kg/m2 inclusive
  • No significant abnormal findings at the screening physical examination as evaluated by the Investigator;
  • Normal laboratory values (or abnormal but not clinically significant) at screening as determined by the Investigator;
  • Subject is willing to remain in the clinic for the screening visit and 2 overnight treatment visits (approximately 36 hours for the treatment visit)
  • Must be able to swallow gelatin capsules;
  • Must be willing to remain in the clinic for the treatment visits

Exclusion criteria

  • Known hypersensitivity to Clomid;
  • Abnormal screening visit vital signs or clinical laboratory evaluation considered clinically significant by the Investigator;
  • A hematocrit >54% or a hemoglobin >17 g/dL.
  • Subject with a significant organ abnormality or disease as determined by the Investigator;
  • Any medical condition that would interfere with the study as determined by the Investigator;
  • Participation in a clinical trial with investigational medication within 30 days prior to study medication administration;
  • An acute illness within 5 days of study medication administration;
  • Positive urine drug screen at the screening visit;
  • Known history of HIV and/or Hepatitis B or C
  • Tobacco (nicotine products) use in the 3 months prior to the study;
  • A mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study and/or evidence of an uncooperative attitude, as determined by the Investigator;
  • History of venous thromboembolic disease (e.g. deep vein thrombosis or pulmonary embolism);
  • History of myocardial infarction, unstable angina, symptomatic heart failure, ventricular dysrhythmia, or known history of QTc interval prolongation;
  • An employee or family member of an employee of the study site or the Sponsor;
  • Previous participation in a clinical study of Androxal.

Treatment and study plan

Androxal 25 mg Capsules

Drug

Primary outcomes

  1. • Cmax of a single dose of 25 mg of Androxal in male subjects in the fed state and fasted state.

    Time frame: 24 hour

Sponsors and collaborators

Lead sponsor

Repros Therapeutics Inc.

Industry

Registry information

Official study title

AN OPEN-LABEL, RANDOMIZED, SINGLE-DOSE, TWO-WAY CROSSOVER STUDY TO EVALUATE THE EFFECT OF FOOD UPON THE PHARMACOKINETICS OF ANDROXAL

Important dates

Study start
2014
Primary completion
2014
Study completion
2014
First posted
May 23, 2014
Registry last updated
Aug 11, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.